Poland Anti Aging Therapeutics Market Report 2022 to 2030

Poland Anti Aging Therapeutics Market Analysis

$ 3999

Poland's anti-ageing therapeutics market is expected to witness growth from $4 Mn in 2022 to $12 Mn in 2030 with a CAGR of 16.98% for the year 2022-30. The rising awareness about anti-ageing therapeutics and recent technological advancements in Poland has led to market expansion. The Poland anti-ageing therapeutics market is segmented by product, treatment, target group, type of ageing, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the major competitors in the market are Intelliseq, Pure Biologics, and NuSirt.

ID: IN10PLPH030 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Parul Choudhary

Buy Now

Poland Anti-Aging Therapeutics Market Executive Summary

Poland anti-ageing therapeutics market size is at around $4 Mn in 2022 and is projected to reach $12 Mn in 2030, exhibiting a CAGR of 16.98% during the forecast period. The health minister for Poland stated on Sunday that the nation is methodically moving toward allocating 7% of its GDP to healthcare. Government plans had been expanded by $9.8 Bn. Geriatrics has been deemed a top specialization because nearly 70% of people 60 and older are affected by multiple diseases. The demand for medical services and medications will rise in the upcoming years, he continued, and so will government expenditure on health care. The cost of healthcare as a %age of GDP is presently just over 6%, up from 4.5% in 2015, he continued.

Ageing refers to physical changes that occur as a result of ageing, which is understood to be normal processes that affect everyone and are linked to the passing of time. Despite the 'normalness' of the process, there is a trend toward treating ageing as a disease that needs to be properly diagnosed. A concentrate of human blood platelets suspended in a small quantity of plasma known as autologous platelet-rich plasma has thrombocyte concentrations that are higher than the initial concentration. Autologous plasma needs to have at least 1 Mn platelets per 5 cc of plasma in order to have significant healing potential. The formation of a blood clot is the fundamental prerequisite for starting repair and regenerative processes in vivo. Additionally, as they degranulate, platelets release a variety of growth factors, including PDGF, TGF-, EGF, FGF, and VEGF, which play a role in an immune reaction as well as tissue healing in addition to blood coagulation. The increasing acceptance of regenerative medicine as the medicine of the future is reflected in the use of platelet-rich therapies in Poland. It is undetermined which ingredients are necessary and preferred, and which are harmful for tissue regeneration, without appropriate control techniques or optimization of several variables (such as concentration or ratio of growth factors during PRP preparation).

Market Dynamics

Market Growth Drivers Analysis

There is an increasing need for anti-aging alternatives as people become more conscious of how aging affects their appearance and health. The Poland anti-aging therapeutics market may expand as a result of the rise in the appeal of anti-aging procedures and commodities. Technology developments have resulted in the emergence of fresh and cutting-edge anti-aging treatments and goods. Consumers find these new goods more appealing because they are more efficient and possess fewer side effects than conventional treatments.

Market Restraints

Many anti-aging procedures and goods are costly making many customers unable to purchase them. This might prevent Poland anti-aging therapeutics market from expanding, especially among those with poor incomes. The complex regulatory climate for anti-aging goods and treatments in Poland might restrain market expansion. Initial development and commercialization of new treatments could be slowed down if companies have trouble getting regulatory approvals for new goods and therapies. Some anti-aging treatments and products come with serious risks and side effects, which may discourage customers from using them. This might prevent the market from expanding, especially among people who are worried about the risks and negative impacts that these treatments might have.

Competitive Landscape

Key Players

Selvita (POL)
Polpharma Biologics (POL)
Jagiellońskie Centrum Innowacji (POL)
Intelliseq (POL)
Pure Biologics (POL)
NuSirt
OneSkin Technologies
PharmatrophiX
Proteostasis Therapeutics
Retrotope
Stealth Biotherapeutics

Healthcare Policies and Regulatory Landscape

The Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) in Poland is the regulatory agency in charge of regulating and monitoring the approval of anti-aging medications. A government organization, URPL works under the direction of the Ministry of Health. Its primary responsibility is to review and authorize new medications and medical equipment for use in Poland. Companies must present a dossier of data to URPL that demonstrates the product's safety, effectiveness, and quality in order to get approval for an anti-aging drug. Following an evaluation of the file, URPL will decide whether or not to approve the drug for use in Poland. URPL also observes the safety of drugs that are already on the market and has the power to take action if it becomes aware of any safety issues or concerns. If a product is discovered to be unsafe, it may be necessary for businesses to alter the labeling on the product or even remove it from the market.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Aging Therapeutics Market Segmentation

By Product (Revenue, USD Billion):

Anti-Wrinkle
Hair Color
Ultraviolet (UV) Absorption
Anti-Stretch Mark
Others

By Treatment (Revenue, USD Billion):

Hair Restoration
Anti-Pigmentation
Adult Acne Therapy
Breast Augmentation
Liposuction
Chemical Peel
Others

By Target Group (Revenue, USD Billion):

Male
Female

By Type of Aging (Revenue, USD Billion):

Cellular Aging
Immune Aging
Metabolic Aging
Others

By Type of Molecules (Revenue, USD Billion):

Biologics
Small Molecules

By Mechanism of Action (Revenue, USD Billion):

Senolytic
Cell Regeneration
mTOR inhibitor/Modulator
AMP-kinase/AMP Activator
Mitochondria Inhibitor/Modulator
Others

By Ingredient (Revenue, USD Billion):

Retinoid
Hyaluronic Acid
Alpha Hydroxy Acid
Others

By Distribution Channel (Revenue, USD Billion):

Pharmacies
Stores
Online Stores

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.